domingo, 25 de setembro de 2011

Breast-Cancer Adjuvant Therapy with Zoledronic Acid - Online first in NEJM

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

Robert  E. Coleman, M.B., B.S., M.D., Helen Marshall, M.Sc., David Cameron,
M.B., B.S., M.D., David Dodwell, M.B., Ch.B., M.D., Roger Burkinshaw,
B.Sc., Maccon Keane, M.D., Miguel Gil, M.D., Stephen J. Houston, M.B.,
B.S., M.D., Robert J. Grieve, M.B., Ch.B., Peter J. Barrett-Lee, M.B.,
B.S., M.D., Diana Ritchie, M.B., Ch.B., M.D., Julia Pugh, C.I.M.Dip.,
Claire Gaunt, B.Sc., Una Rea, B.Sc., Jennifer Peterson, B.App.Sc.,
Claire Davies, B.Sc., Victoria Hiley, B.Sc., Walter Gregory, Ph.D., and
Richard Bell, M.B., B.S. for the AZURE Investigators
September 25, 2011
(10.1056/NEJMoa1105195)

Abstract

Background

Data suggest that the adjuvant use of bisphosphonates reduces rates of
recurrence and death in patients with early-stage breast cancer. We
conducted a study to determine whether treatment with zoledronic acid,
in addition to standard adjuvant therapy, would improve disease outcomes
in such patients.

Methods

In this open-label phase 3 study, we randomly assigned 3360 patients to
receive standard adjuvant systemic therapy either with or without
zoledronic acid. The zoledronic acid was administered every 3 to 4 weeks
for 6 doses and then every 3 to 6 months to complete 5 years of
treatment. The primary end point of the study was disease-free survival.
A second interim analysis revealed that a prespecified boundary for
lack of benefit had been crossed.

Results

At a median follow-up of 59 months, there was no significant between-group
difference in the primary end point, with a rate of disease-free
survival of 77% in each group (adjusted hazard ratio in the zoledronic
acid group, 0.98; 95% confidence interval [CI], 0.85 to 1.13; P=0.79).
Disease recurrence or death occurred in 377 patients in the zoledronic
acid group and 375 of those in the control group. The numbers of deaths —
243 in the zoledronic acid group and 276 in the control group — were
also similar, resulting in rates of overall survival of 85.4% in the
zoledronic acid group and 83.1% in the control group (adjusted hazard
ratio, 0.85; 95% CI, 0.72 to 1.01; P=0.07). In the zoledronic acid
group, there were 17 confirmed cases of osteonecrosis of the jaw
(cumulative incidence, 1.1%; 95% CI, 0.6 to 1.7; P<0.001) and 9
suspected cases; there were no cases in the control group. Rates of
other adverse effects were similar in the two study groups.

Conclusions

These findings do not support the routine use of zoledronic acid in the
adjuvant management of breast cancer. (Funded by Novartis
Pharmaceuticals and the National Cancer Research Network; AZURE Current
Controlled Trials number, ISRCTN79831382.)
Read the article: http://bit.ly/oDOscH

Clique aqui!

2015 A.C. Camargo academic journals acesso aberto adverse drug reactions alergia alquilantes alto custo ambiente analgésicos anomalias vasculares anti-eméticos anti-helmínticos anti-histamínico antianêmicos antiangiogênico anticâncer anticoagulantes antifúngicos antiprotozoários antivirais artemisinina arXiv asma asthma atopia atualização aula aulas auto-arquivamento avastin avermectina bevacizumab biologicals bioRxiv Blogger brain tumor cancer cancerologia pediátrica Carlos Chagas carne vermelha cauterização Ceará child chronic fatigue syndrome ciência ciência brasileira ciências biológicas e da saúde cientistas influentes cirurgia CLI conselho internacional crime virtual CT scans Curtis Harris darbopoietina dermatite diabetes dieta disautonomia dislipidemias doença renal doenças cardíacas doenças parasitárias dor DPOC eczema editoras predatórias efeitos adversos eficácia ensino e pesquisa eritropoietina erlotinib ESA escleroterapia estatinas esteróides estilo de vida exercícios F1000Research farmacogenética farmacologia fatores de crescimento fibromialgia Figshare Fisiologia e Medicina fitness flu FMJ fosfoetanolamina fraude acadêmica fraude eletrônica genetics glioblastoma gliomas Google Books gordos green way Harald zur Hausen hemangiomas hemophagocytic lymphohistiocytosis horário imagem immunology imunossupressores imunoterapia infecção urinária inibidores de ECA inibidores tirosina-quinase iniciação científica insulina irracionalismo ivermectina Jeffrey Beall journal hijack Lectures lepra leucemia leukemia linfangiomas Mac OS X macrophage activation syndrome magrinhas mal-formações March for Science Marcha pela Ciência medicina personalizada meta-análise Milton Santos modelos monoclonais monoclonal antibody mortalidade morte mudança Mulliken neuro-oncologia neuroblastoma neurology ngram viewer Nobel Nobel em Medicina ou Fisiologia novas drogas novos tratamentos obesidade ômega 3 open access osteoporose Osvaldo Cruz pediatria pediatric cancer pediatric tumors pediatrics peer review PeerJ personalized medicine PET/CT pharmacogenetics pharmacological treatment pharmacology plágio política de C&T posters postprints predatory publishers Preprints pressão arterial prevenção progressista projeto de pesquisa propranolol próstata publicação publicação científica publicações publication pubmed Python quimioterapia radiation radioterapia rapamycin recidiva regressão espontânea resposta resultados retrospectiva revisão por pares risco Satoshi Ömura Scholarly Open Access science ScienceNOW seguimento selênio self-archiving sequestro de periódico científico serotonina SIDA sildenafil slides sobrevida sulfa suplementos survival tacerva targeted therapy temozolamida temozolomide terapia alternativa tireóide tratamento tuberculose tumores cerebrais tumores pediátricos vaccine vacina via dourada via verde vitamina E vitaminas William C. Campbell Youyou Tu

Postagens populares